$サイロス ファーマシューティカルズ(SYRS.US)$Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.86) by 88.37 percent. This is a 88.24 percent increase over losses of $(0.85) per share from the same period last year.
$サイロス ファーマシューティカルズ(SYRS.US)$Posted PR of FDA fast track Tuesday PM @4.50 PS! Slow but nice climb! How far will it go? Give us a bita love if you are riding! Hehehe
$サイロス ファーマシューティカルズ(SYRS.US)$Syros Receives Fast Track Designation From The FDA For Tamibarotene For The Treatment Of Newly Diagnosed Unfit AML With RARA Gene Overexpression
$サイロス ファーマシューティカルズ(SYRS.US)$ From my study, the trend should be going to rebounce soon, current price closed to 38.2% fibonacci, and volume keep in lower. (Disclaimer: Just for my own study, I'm not responsible on any loss caused.)
I love me :
I'm still here any thoughts on after hours... won't hold you to anything but how confident are you on it getting to $10.. on the chart you referred to earlier.
サイロス ファーマシューティカルズに関するコメント
From my study, the trend should be going to rebounce soon, current price closed to 38.2% fibonacci, and volume keep in lower. (Disclaimer: Just for my own study, I'm not responsible on any loss caused.)
まだコメントはありません